# Ennis, Inc.: financial statements, quarterly

EBF · NYSE · CIK 33002 · [Communication](/sectors/communication.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/ebf.md) · [Financials](/companies/ebf/financials.md) · [Filings](/companies/ebf/filings.md) · [Insiders](/companies/ebf/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/ebf/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2024 (2023-11-30) | Q4 FY2024 (2024-02-29) | Q1 FY2025 (2024-05-31) | Q2 FY2025 (2024-08-31) | Q3 FY2025 (2024-11-30) | Q4 FY2025 (2025-02-28) | Q1 FY2026 (2025-05-31) | Q2 FY2026 (2025-08-31) | Q3 FY2026 (2025-11-30) | Q4 FY2026 (2026-02-28) | Q1 FY2027 (2026-05-31) | Q2 FY2027 (2026-08-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [105](/filings/0000950170-25-002567.md) | [97.4 d](/filings/0001193125-26-213764.md) | [103](/filings/0000950170-25-091277.md) | [99.0](/filings/0001193125-25-229282.md) | [99.8](/filings/0001193125-26-005532.md) | [92.7 d](/filings/0001193125-26-213764.md) | [97.2](/filings/0001193125-26-291652.md) | [98.7](/filings/0001193125-26-413659.md) | [100](/filings/0001193125-26-005532.md) | [96.4 d](/filings/0001193125-26-213764.md) | [98.6](/filings/0001193125-26-291652.md) | [102](/filings/0001193125-26-413659.md) |
| Cost of revenue | $m | [74.1](/filings/0000950170-25-002567.md) | [69.8 d](/filings/0001193125-26-213764.md) | [72.2](/filings/0000950170-25-091277.md) | [69.3](/filings/0001193125-25-229282.md) | [70.5](/filings/0001193125-26-005532.md) | [65.3 d](/filings/0001193125-26-213764.md) | [67.0](/filings/0001193125-26-291652.md) | [68.6](/filings/0001193125-26-413659.md) | [68.2](/filings/0001193125-26-005532.md) | [68.2 d](/filings/0001193125-26-213764.md) | [67.5](/filings/0001193125-26-291652.md) | [71.5](/filings/0001193125-26-413659.md) |
| Gross profit | $m | [30.5](/filings/0000950170-25-002567.md) | [27.7 d](/filings/0001193125-26-213764.md) | [30.9](/filings/0000950170-25-091277.md) | [29.8](/filings/0001193125-25-229282.md) | [29.2](/filings/0001193125-26-005532.md) | [27.4 d](/filings/0001193125-26-213764.md) | [30.2](/filings/0001193125-26-291652.md) | [30.1](/filings/0001193125-26-413659.md) | [32.0](/filings/0001193125-26-005532.md) | [28.1 d](/filings/0001193125-26-213764.md) | [31.1](/filings/0001193125-26-291652.md) | [30.5](/filings/0001193125-26-413659.md) |
| Selling, general and administrative | $m | [17.4](/filings/0000950170-25-002567.md) | [14.7 d](/filings/0001193125-26-213764.md) | [17.2](/filings/0000950170-25-091277.md) | [16.6](/filings/0001193125-25-229282.md) | [16.3](/filings/0001193125-26-005532.md) | [15.3 d](/filings/0001193125-26-213764.md) | [16.9](/filings/0001193125-26-291652.md) | [17.7](/filings/0001193125-26-413659.md) | [17.0](/filings/0001193125-26-005532.md) | [16.1 d](/filings/0001193125-26-213764.md) | [17.5](/filings/0001193125-26-291652.md) | [16.9](/filings/0001193125-26-413659.md) |
| Operating income | $m | [13.1](/filings/0000950170-25-002567.md) | [12.9 d](/filings/0001193125-26-213764.md) | [13.7](/filings/0000950170-25-091277.md) | [13.2](/filings/0001193125-25-229282.md) | [13.0](/filings/0001193125-26-005532.md) | [12.0 d](/filings/0001193125-26-213764.md) | [13.3](/filings/0001193125-26-291652.md) | [12.4](/filings/0001193125-26-413659.md) | [15.0](/filings/0001193125-26-005532.md) | [12.0 d](/filings/0001193125-26-213764.md) | [13.6](/filings/0001193125-26-291652.md) | [13.6](/filings/0001193125-26-413659.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [3.9](/filings/0000950170-25-002567.md) | [3.7 d](/filings/0001193125-26-213764.md) | [4.1](/filings/0000950170-25-091277.md) | [3.9](/filings/0001193125-25-229282.md) | [3.9](/filings/0001193125-26-005532.md) | [3.4 d](/filings/0001193125-26-213764.md) | [3.7](/filings/0001193125-26-291652.md) | [5.0](/filings/0001193125-26-413659.md) | [4.1](/filings/0001193125-26-005532.md) | [3.2 d](/filings/0001193125-26-213764.md) | [3.8](/filings/0001193125-26-291652.md) | [3.7](/filings/0001193125-26-413659.md) |
| Net income | $m | [9.9](/filings/0000950170-25-002567.md) | [10.1 d](/filings/0001193125-26-213764.md) | [10.7](/filings/0000950170-25-091277.md) | [10.3](/filings/0001193125-25-229282.md) | [10.2](/filings/0001193125-26-005532.md) | [9.0 d](/filings/0001193125-26-213764.md) | [9.8](/filings/0001193125-26-291652.md) | [13.2](/filings/0001193125-26-413659.md) | [10.8](/filings/0001193125-26-005532.md) | [8.8 d](/filings/0001193125-26-213764.md) | [9.9](/filings/0001193125-26-291652.md) | [9.4](/filings/0001193125-26-413659.md) |
| Diluted EPS | $ per share | [0.38](/filings/0000950170-25-002567.md) | not reported | [0.41](/filings/0000950170-25-091277.md) | [0.40](/filings/0001193125-25-229282.md) | [0.39](/filings/0001193125-26-005532.md) | not reported | [0.38](/filings/0001193125-26-291652.md) | [0.51](/filings/0001193125-26-413659.md) | [0.42](/filings/0001193125-26-005532.md) | not reported | [0.39](/filings/0001193125-26-291652.md) | [0.37](/filings/0001193125-26-413659.md) |
| Basic EPS | $ per share | [0.38](/filings/0000950170-25-002567.md) | not reported | [0.41](/filings/0000950170-25-091277.md) | [0.40](/filings/0001193125-25-229282.md) | [0.39](/filings/0001193125-26-005532.md) | not reported | [0.38](/filings/0001193125-26-291652.md) | [0.51](/filings/0001193125-26-413659.md) | [0.43](/filings/0001193125-26-005532.md) | not reported | [0.39](/filings/0001193125-26-291652.md) | [0.37](/filings/0001193125-26-413659.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2024 (2023-11-30) | FY2024 (2024-02-29) | Q1 FY2025 (2024-05-31) | Q2 FY2025 (2024-08-31) | Q3 FY2025 (2024-11-30) | FY2025 (2025-02-28) | Q1 FY2026 (2025-05-31) | Q2 FY2026 (2025-08-31) | Q3 FY2026 (2025-11-30) | FY2026 (2026-02-28) | Q1 FY2027 (2026-05-31) | Q2 FY2027 (2026-08-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [83.9](/filings/0000950170-24-002337.md) | [81.6](/filings/0000950170-25-070268.md) | [91.4](/filings/0000950170-24-077829.md) | [100.0](/filings/0000950170-24-112399.md) | [55.7](/filings/0000950170-25-002567.md) | [67.0](/filings/0001193125-26-213764.md) | [32.6](/filings/0000950170-25-091277.md) | [31.9](/filings/0001193125-25-229282.md) | [31.3](/filings/0001193125-26-005532.md) | [34.6](/filings/0001193125-26-413659.md) | [49.1](/filings/0001193125-26-291652.md) | [54.0](/filings/0001193125-26-413659.md) |
| Current assets | $m | [199](/filings/0000950170-24-002337.md) | [201](/filings/0000950170-25-070268.md) | [211](/filings/0000950170-24-077829.md) | [212](/filings/0000950170-24-112399.md) | [152](/filings/0000950170-25-002567.md) | [153](/filings/0001193125-26-213764.md) | [136](/filings/0000950170-25-091277.md) | [139](/filings/0001193125-25-229282.md) | [133](/filings/0001193125-26-005532.md) | [132](/filings/0001193125-26-413659.md) | [143](/filings/0001193125-26-291652.md) | [149](/filings/0001193125-26-413659.md) |
| Total assets | $m | [401](/filings/0000950170-24-002337.md) | [399](/filings/0000950170-25-070268.md) | [406](/filings/0000950170-24-077829.md) | [407](/filings/0000950170-24-112399.md) | [346](/filings/0000950170-25-002567.md) | [349](/filings/0001193125-26-213764.md) | [362](/filings/0000950170-25-091277.md) | [362](/filings/0001193125-25-229282.md) | [354](/filings/0001193125-26-005532.md) | [357](/filings/0001193125-26-413659.md) | [364](/filings/0001193125-26-291652.md) | [365](/filings/0001193125-26-413659.md) |
| Current liabilities | $m | [34.3](/filings/0000950170-24-002337.md) | [33.8](/filings/0000950170-25-070268.md) | [36.8](/filings/0000950170-24-077829.md) | [33.9](/filings/0000950170-24-112399.md) | [32.3](/filings/0000950170-25-002567.md) | [33.3](/filings/0001193125-26-213764.md) | [45.8](/filings/0000950170-25-091277.md) | [41.2](/filings/0001193125-25-229282.md) | [35.0](/filings/0001193125-26-005532.md) | [35.4](/filings/0001193125-26-413659.md) | [40.7](/filings/0001193125-26-291652.md) | [39.3](/filings/0001193125-26-413659.md) |
| Total liabilities | $m | [53.6](/filings/0000950170-24-002337.md) | [49.3](/filings/0000950170-25-070268.md) | [51.8](/filings/0000950170-24-077829.md) | [48.4](/filings/0000950170-24-112399.md) | [48.4](/filings/0000950170-25-002567.md) | [47.0](/filings/0001193125-26-213764.md) | [60.5](/filings/0000950170-25-091277.md) | [56.5](/filings/0001193125-25-229282.md) | [49.5](/filings/0001193125-26-005532.md) | [48.2](/filings/0001193125-26-413659.md) | [52.9](/filings/0001193125-26-291652.md) | [50.9](/filings/0001193125-26-413659.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [348](/filings/0000950170-25-002567.md) | [350](/filings/0001193125-26-213764.md) | [354](/filings/0001193125-25-229282.md) | [358](/filings/0001193125-26-005532.md) | [298](/filings/0001193125-26-005532.md) | [302](/filings/0001193125-26-413659.md) | [301](/filings/0001193125-26-413659.md) | [305](/filings/0001193125-26-413659.md) | [305](/filings/0001193125-26-005532.md) | [309](/filings/0001193125-26-413659.md) | [311](/filings/0001193125-26-413659.md) | [314](/filings/0001193125-26-413659.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Current portion of debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2024 (2023-11-30) | Q4 FY2024 (2024-02-29) | Q1 FY2025 (2024-05-31) | Q2 FY2025 (2024-08-31) | Q3 FY2025 (2024-11-30) | Q4 FY2025 (2025-02-28) | Q1 FY2026 (2025-05-31) | Q2 FY2026 (2025-08-31) | Q3 FY2026 (2025-11-30) | Q4 FY2026 (2026-02-28) | Q1 FY2027 (2026-05-31) | Q2 FY2027 (2026-08-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [17.6 d](/filings/0000950170-25-002567.md) | [16.6 d](/filings/0001193125-26-213764.md) | [23.1](/filings/0000950170-25-091277.md) | [11.8 d](/filings/0001193125-25-229282.md) | [18.2 d](/filings/0001193125-26-005532.md) | [12.8 d](/filings/0001193125-26-213764.md) | [8.0](/filings/0001193125-26-291652.md) | [10.5 d](/filings/0001193125-26-413659.md) | [16.4 d](/filings/0001193125-26-005532.md) | [17.9 d](/filings/0001193125-26-213764.md) | [21.2](/filings/0001193125-26-291652.md) | [12.9 d](/filings/0001193125-26-413659.md) |
| Capital expenditure | $m | [1.2 d](/filings/0000950170-25-002567.md) | [1.6 d](/filings/0001193125-26-213764.md) | [2.5](/filings/0000950170-25-091277.md) | [1.1 d](/filings/0001193125-25-229282.md) | [0.6 d](/filings/0001193125-26-005532.md) | [1.6 d](/filings/0001193125-26-213764.md) | [1.4](/filings/0001193125-26-291652.md) | [1.4 d](/filings/0001193125-26-413659.md) | [0.7 d](/filings/0001193125-26-005532.md) | [8.2 d](/filings/0001193125-26-213764.md) | [0.4](/filings/0001193125-26-291652.md) | [1.6 d](/filings/0001193125-26-413659.md) |
| Dividends paid | $m | [6.5 d](/filings/0000950170-25-002567.md) | [6.5 d](/filings/0001193125-26-213764.md) | [6.5](/filings/0000950170-25-091277.md) | [6.5 d](/filings/0001193125-25-229282.md) | [72.3](/filings/0000950170-25-002567.md) | [6.7 d](/filings/0001193125-26-213764.md) | [6.6](/filings/0001193125-26-291652.md) | [6.5 d](/filings/0001193125-26-413659.md) | [6.4 d](/filings/0001193125-26-005532.md) | [6.4 d](/filings/0001193125-26-213764.md) | [6.4](/filings/0001193125-26-291652.md) | [6.4 d](/filings/0001193125-26-413659.md) |
| Share repurchases | $m | [0.0 d](/filings/0000950170-25-002567.md) | [0.6 d](/filings/0001193125-26-213764.md) | [1.8](/filings/0000950170-25-091277.md) | [0.0 d](/filings/0001193125-25-229282.md) | [0.0 d](/filings/0001193125-26-005532.md) | [0.0 d](/filings/0001193125-26-213764.md) | [5.0](/filings/0001193125-26-291652.md) | [3.5 d](/filings/0001193125-26-413659.md) | [5.9 d](/filings/0001193125-26-005532.md) | [0.0 d](/filings/0001193125-26-213764.md) | [0.0](/filings/0001193125-26-291652.md) | [0.0 d](/filings/0001193125-26-413659.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquireProductiveAssets
- Dividends paid: us-gaap:PaymentsOfDividendsCommonStock, us-gaap:PaymentsOfDividends
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2023 (2022-11-30) | Q1 FY2024 (2023-05-31) | Q2 FY2024 (2023-08-31) | Q3 FY2024 (2023-11-30) | Q1 FY2025 (2024-05-31) | Q2 FY2025 (2024-08-31) | Q3 FY2025 (2024-11-30) | Q1 FY2026 (2025-05-31) | Q2 FY2026 (2025-08-31) | Q3 FY2026 (2025-11-30) | Q1 FY2027 (2026-05-31) | Q2 FY2027 (2026-08-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [25.9](/filings/0000950170-24-002337.md) | [26.0](/filings/0000950170-24-077829.md) | [26.1](/filings/0000950170-24-112399.md) | [26.1](/filings/0000950170-25-002567.md) | [26.3](/filings/0000950170-25-091277.md) | [26.1](/filings/0001193125-25-229282.md) | [26.1](/filings/0001193125-26-005532.md) | [26.0](/filings/0001193125-26-291652.md) | [25.8](/filings/0001193125-26-413659.md) | [25.5](/filings/0001193125-26-005532.md) | [25.5](/filings/0001193125-26-291652.md) | [25.3](/filings/0001193125-26-413659.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 25,317,786 at 2026-09-25, from the cover of the [10-Q filed 2026-10-05](/filings/0001193125-26-413659.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:18 ET. No prices; not investment advice.